NasdaqGS:RAREBiotechs
How Setrusumab Trial Setbacks and Securities Suits May Impact Ultragenyx Pharmaceutical (RARE) Investors
In past months, several law firms announced securities class actions against Ultragenyx Pharmaceutical, alleging the company misled investors about the reliability and risks of Phase III Orbit and Cosmic trials for setrusumab in osteogenesis imperfecta, after the studies failed to reach statistical significance.
The litigation raises questions about Ultragenyx’s clinical disclosure practices and could influence how investors view the company’s risk profile, capital allocation, and future...